ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Prosthetic Valve Endocarditis after TAVR and SAVR: Insights from the PARTNER Trials

Thursday, November 7, 2019

Submitted by

Mark Ferguson

Source

Source Name: Circulation

Source URL: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.119.041399

Author(s)

Matthew R. Summers, Martin B. Leon, Craig R. Smith, Susheel K. Kodali, Vinod H. Thourani, Howard C. Herrmann, Raj R. Makkar, Philippe Pibarot, John G. Webb, Jonathon Leipsic, Maria C. Alu, Aaron Crowley, Rebecca T. Hahn, Samir R. Kapadia, E. Murat Tuzcu, Lars Svensson, Paul C. Cremer, and Wael A. Jaber

Data from the PARTNER trials were assessed regarding post-procedural prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement and surgical aortic valve replacement. The timing and rates of PVE were similar between the groups, and they had a similar high mortality.